The meeting that will bring together international experts at the Champalimaud Foundation in Lisbon, under the motto Psychedelic Therapy: From Evidence to Equity, is scheduled for October 1st.
For one day, the debate will focus on the challenges and opportunities of psychedelic-assisted therapy, a topic that has been on the agenda for the European medical community, especially since Norway made ketamine-assisted treatment in the context of psychotherapy reimbursable in all public hospitals in August.
"This one-day event will bring together clinicians, researchers, patient representatives, policy makers and ethicists to explore the landscape of psychedelic-assisted care through the lens of the four pillars of medical ethics: beneficence, autonomy, non-maleficence and justice," reads the Champalimaud Foundation's official website.
Safety, regulation, therapeutic practices and future directions will be issues addressed throughout the day, with a view to ensuring "equitable access to psychedelic-assisted care."
The line-up includes more than a dozen speakers. Among them, Albino J. Oliveira-Maia, Researcher and Director of the Champalimaud Foundation's Neuropsychiatry Unit, Alessandra Martini, Advisor to the European Commission, and Carolina Seybert, Clinical Psychologist and Researcher at the Champalimaud Foundation's Neuropsychiatry Unit.
Lisbon will also be visited by Neşe Devenot, assistant professor at Johns Hopkins University, Tiago Machado, clinical advisor at Infarmed, and Thomas Clausen, chief scientist at the European Union Agency for Drugs.
